How much funding has Adaptive Biotechnologies raised?

Adaptive Biotechnologies has raised $120.0M in total funding, most recently a Series D round.

Where is Adaptive Biotechnologies headquartered?

Adaptive Biotechnologies is headquartered in Seattle, Washington, United States.

What industry is Adaptive Biotechnologies in?

Adaptive Biotechnologies operates in Biotech, Healthcare.

How many employees does Adaptive Biotechnologies have?

Adaptive Biotechnologies has 501-1000 employees.

Adaptive Biotechnologies

Q: When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009.

IPO

Powering the age of immune medicine

Public · Seattle, United States · Founded 2009 · $120.0M raised

Biotech

Healthcare

Headquarters: Seattle, Washington
Employees: 501–1000
Founded: 2009
Business Model: B2B
Website: adaptivebiotech.com

Total Funding: $120.0M
Last Round: $120.0M Series DMay 2019
Rounds: 2
Type: Public

About

Adaptive Biotechnologies was founded in 2009 by Chad Robins and Harlan Robins, leveraging research from Fred Hutchinson Cancer Center in Seattle. The company sequences and interprets T-cell and B-cell receptors to detect and monitor disease. Its flagship product clonoSEQ is an FDA-cleared next-generation sequencing test for minimal residual disease (MRD) monitoring in blood cancers. Adaptive went public on Nasdaq in 2019 (ticker: ADPT).

Summary

Adaptive Biotechnologies is a Biotech company based in Seattle, United States, founded in 2009. It has raised $120.0M in total across 2 rounds, most recently a $120.0M Series D round in May 2019.

LinkedIn X (Twitter)